ANIXA BIOSCIENCES, INC. Accrued Royalties, Current
ANIXA BIOSCIENCES, INC. (ANIX) had Accrued Royalties, Current of $626.00 thousand as of 2026-07-31, per its 10-Q filed 2026-09-09.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedRoyaltiesCurrent · last filed 2026-09-09
- 2026-07-31: Accrued Royalties, Current $626.00K.
- 2026-04-30: Accrued Royalties, Current $626.00K.
- 2026-01-31: Accrued Royalties, Current $626.00K.
- 2025-10-31: Accrued Royalties, Current $626.00K.
| Period end | Accrued Royalties, Current |
|---|---|
| 2026-07-31 | $626.00K 10-Q · filed 2026-09-09 |
| 2026-04-30 | $626.00K 10-Q · filed 2026-06-10 |
| 2026-01-31 | $626.00K 10-Q · filed 2026-03-09 |
| 2025-10-31 | $626.00K 10-Q · filed 2026-09-09 |
| 2025-07-31 | $626.00K 10-Q · filed 2025-09-10 |
| 2025-04-30 | $626.00K 10-Q · filed 2025-05-28 |
| 2025-01-31 | $626.00K 10-Q · filed 2025-03-11 |
| 2024-10-31 | $626.00K 10-K · filed 2026-01-12 |
| 2024-07-31 | $626.00K 10-Q · filed 2024-09-06 |
| 2023-10-31 | $626.00K 10-K · filed 2025-01-10 |
| 2019-01-31 | $366.67K 10-Q · filed 2019-03-13 |
| 2018-10-31 | $366.67K 10-Q · filed 2019-03-13 |
| 2018-07-31 | $366.67K 10-Q · filed 2018-09-07 |
| 2018-04-30 | $246.18K 10-Q · filed 2018-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |